The presented study aimed to compare the real-world data on treatment retention in ATTRA (Anti-TNF Treatment in Rheumatoid Arthritis) registry patients receiving first-line treatment with a TNFi combined with csDMARDs and in those treated with a TNFi alone. Here, TNF is linked to rheumatoid arthritis.